New product: Ibrance (palbociclib) film-coated tablets (various strengths)
This is licensed for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer, in combination with an aromatase inhibitor; or in combination with fulvestrant in women who have received prior endocrine therapy.
Source:
electronic Medicines compendium